LFVN Lifevantage

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against LifeVantage Corporation (LFVN) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Utah District Court on behalf of all persons or entities who acquired LifeVantage Corporation (NASDAQ:LFVN) securities between November 4, 2015 and September 13, 2016 (the “Class Period”).

LifeVantage identifies, researches, develops, and distributes nutraceutical dietary supplements and skin care products. LifeVantage Corporation sells its products through a network of independent distributors and preferred customers in the United States, Japan, Hong Kong, Australia, Canada, the Philippines, Mexico, and Thailand. The Company also sells its products online.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) LifeVantage lacked effective internal financial controls; (ii) as a result, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (iii) as a result of the foregoing, LifeVantage’s public statements were materially false and misleading at all relevant times.

On September 13, 2016, post-market, LifeVantage issued a press release and filed a Current Report on Form 8-K with the Securities and Exchange Commission, announcing a delay in the release of the Company’s fourth quarter and fiscal year 2016 financial results, citing an internal review “relate[d] to sales of the Company’s products in certain international markets and the determination of revenue and the deductibility of commission and incentive expenses associated with such sales, as well as the policies and procedures related to sales in those specific markets.”

On this news, LifeVantage stock fell $1.32, or 12.69%, to close at $9.08 on September 14, 2016.

If you acquired LifeVantage securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.

EN
16/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lifevantage

 PRESS RELEASE

LifeVantage to Participate in Water Tower Fireside Chat on Thursday, D...

LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025 SALT LAKE CITY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming Water Tower Fireside Chat Series on Thursday, December 11, 2025. The webcast of the fireside chat will begin at approximately 2:00 p.m. Eastern Time on...

 PRESS RELEASE

New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Produ...

New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health New in vitro research shows P84 influences key gut peptides – including one by more than 1,000% – supporting cellular pathways tied to regulation, repair, and restoration SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological a...

 PRESS RELEASE

LifeVantage Declares Quarterly Dividend

LifeVantage Declares Quarterly Dividend SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a p...

 PRESS RELEASE

LifeVantage Announces Financial Results for the First Quarter of Fisca...

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026 SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period. Excluding the impact of foreign currency fluctuations, first quarter revenue increased approximately 0.3%;...

 PRESS RELEASE

LifeVantage Empowers Consultants to “Love Life & Drive” at Momentum Ac...

LifeVantage Empowers Consultants to “Love Life & Drive” at Momentum Academy 2025 Dallas event delivers new products, tools, and business strategies designed to accelerate performance and leadership SALT LAKE CITY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of , a dynamic, high-impact event that brought together thousands of Consultants from across the U.S. from October 23-25 at the Hilton Anatole in Dallas, TX. This...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch